Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 6031-6040 Newer>

The Motley Fool November 20, 2009 Brian Orelli	This Baby Is a Nice Addition A month into an acquisition, and Merck already sees a benefit.
The Motley Fool November 20, 2009 Brian Orelli	Who's Paying for Health-Care Reform? You are, of course. Ensuring coverage of 94% of eligible Americans will cost a trillion dollars over the next decade, give or take a few billion depending on which chamber the bill is coming out of.
The Motley Fool November 20, 2009 Kris Eddy	Drug Companies Targeted, Again Is a review of drug prices by Congress something to worry about?
BusinessWeek November 19, 2009 Catherine Arnst	Why Drugmakers Don't Twitter The FDA has so far failed to craft rules clarifying how pharmaceutical companies can participate in online discussions.
The Motley Fool November 19, 2009 Brian Orelli	Pfizer Dodges a Bullet The drugmaker slips through an advisory committee unscathed.
The Motley Fool November 19, 2009 Brian Orelli	This Stock Is a Train Wreck Genzyme's string of missteps has investors nervous.
The Motley Fool November 19, 2009 Brian Orelli	Pfizer's Generic Growth, With a Side of Sashimi A move into Japan isn't a bad idea, but it isn't going to save the company either.
Chemistry World November 18, 2009 Sarah Houlton	A pharmaceutical named desire A new drug being developed by Boehringer Ingelheim could give a boost to the sex drive of women with low libido.
The Motley Fool November 18, 2009 Brian Orelli	Your Heart or Your Stomach? It must be disappointing to know that a label change on another drug -- one that isn't even your competition -- is going to hurt sales, but that's the position that Procter & Gamble and AstraZeneca find themselves in.
The Motley Fool November 18, 2009 Brian Orelli	Drug Lowers Cholesterol; Stock Follows ISIS has a hard time at American Heart Association despite good efficacy data.
<Older 6031-6040 Newer> Return to current articles.